Medicines Transparency Alliance02/02/2016 1 MeTA Peru Pedro Yarasca System of public information on prices of Pharmaceutical Products.

Slides:

Advertisements

Similar presentations

Pharmaceutical Policy and Pricing: How are Countries Getting Greater Value? Commonwealth Fund/ Alliance for Health Reform Briefing on Capitol Hill Dr.

Advertisements

Introduction to Pharmacy Course Teacher: Asim Kumar Bepari.

Nedcor Securities Healthcare Conference March 2004.

Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.

ILLEGAL DRUG STORES IN ZAMBIA PRESENTED BY A. PHIRI ARTHUR DAVISON CHILDREN’S HOSPITAL Presented to CSO workshop in Ndola on 29 August 2013.

I&EHL: EU Pharmaceutical Law André den Exter

SG EUROPEAN PHARMACEUTICAL PRICING NERVE CENTRE. ABOUT SIGYN R&D Sigyn R&D is a Croatian company based in Zagreb, established in Tailor made software.

Canadian Generic Pharmaceutical Association Getting to the Heart of Drug Sustainability – The Issues Canada’s Public Policy Forum - Atlantic Summit On.

Medicines Transparency Alliance08/08/ MeTA Peru Country Overview Public Sector Private Sector Civil Society.

Formulary IHE Pharmacy meeting - Den Haag 1. IHE Pharmacy white paper Formularies in the pharmaceutical practice Formularies as set of data in softwares.

Rwanda Social Security Board (RSSB) Medical Insurance Scheme May 2013.

Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)

Commercial (Non Government Sponsored) Health Plan Medical Cost and Premium Trends Pharmaceuticals15%14% 12% 11%1.8% Hospital Inpatient Outpatient2515.

Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.

Analysis of the Pharmaceutical Supply Chain in Jordan Simon Conesa 1, Prashant Yadav 1, Rania Bader 2 (2009) 1 MIT-Zaragoza International Logistics Program,

Procurement and Supply Management in Moldova Laurentiu IONESII.

Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February

REDUCTION OF ‘OUT OF POCKET’ EXPENSES OF PATIENTS THROUGH INNOVATIVE PRACTICES OF THE GOVERNMENT OF WEST BENGAL.

Extraordinary General Meeting of SFEE Re-pricing & New Products Nikos Kefalas, Vice President of SFEE Wednesday, November 27, 2013.

How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of.

Wilbert Bannenberg SARPAM

The Pharmaceutical Industry in Turkey

TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.

The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.

Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.

Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.

Public Procurement in Macedonia Current status. Current public procurement system Decentralized public procurement system Legal framework Institutional.

Chapter 13 Pgs  Listing of goods or items that a business will use in its normal operation.  Each tech is REQUIRED to master the specific.

Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.

“... now is the time to stop butting heads and start linking arms. It is not impossible to work out a united plan that will be acceptable for all, and.

Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.

Tajikistan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.

The Notification Procedure of national telecoms markets Pál Belényesi 27 October 2006.

MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.

State Agency on Public Procurement and Material Reserves under the Government of the Kyrgyz Republic Public Procurement System of the Kyrgyz Republic.

A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)

Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.

Progress and plans for PPM in the WHO Region of the Americas Fifth PPM Subgroup Meeting June, Cairo.

Deploy Operational Controls “Alerts / Approvals / Blocks Presented by: Gary Godfrey Solution Expert November 9, 2015.

ACS Primary Authority Assured Advice James Lowman.

GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.

Ministry of Health of the Kyrgyz Republic The progress in the implementation of the Drug Circulation Program for ( The Decree of the Government.

Centre for Research and Analysis of Public Opinion and Predictions EL- PIKIR Methodology of WHO/HAI (Health Action International)Methodology of WHO/HAI.

CONFERENCE IMPLEMENTATION OF MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE -MiFID- Split, June 2007 OPENING SPEECH Ante Samodol President of the Board.

The community pharmacy environment HMI Public Hearing Set 1 Hearing 2

Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.

ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.

Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.

PAHO has created a mechanism in order that the countries that do not have aptitude to guarantee generic insurances accede to them in an immediate.

M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.

The Law of the KR «On making amendments and changes to certain legislative acts of the KR» 4 th MeTA Forum in the Kyrgyz Republic Bishkek, December 8,

ROLES AND RESPONSIBILITIES OF TFDA ON ADDO PROGRAM

II Volga specialized forum "Medicine. Pharmacy"

Update on EU regulatory developments

Eastern European Partner countries

Bilateral screening: Chapter 1

Logez S, Hutin Y, Somda P, Thualt J, Holloway K

Change in legislation on alcohol, tobacco and drugs in Russia in 2016.

Implementation of the Sustainable Development Goals (SDG) in the Republic of Uzbekistan Geneva, April 12, 2017.

World Health Organization

Entry and Regulation – Evidence from the Health Care Professions

Issues on Dispensing Dr Percy Mahlathi.

IAEA RER/9/141: Improving National Infrastructure for Safety Regional Workshop: Drafting School for Regulations. Radiation Safety Stream Country IAEA.

PRESENTATION OF MONTENEGRO

Economic and Fiscal Considerations of Legalized Cannabis

EUnetHTA Assembly May 2018.

WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.

Geographical Context To familiarise.

Saudi Arabia: Veterinary Pharmaceutical Legislations &

GMP Legal Framework in Kyrgyzstan

Presentation transcript:

Medicines Transparency Alliance02/02/ MeTA Peru Pedro Yarasca System of public information on prices of Pharmaceutical Products

Medicines Transparency Alliance02/02/20162 Analysis of the pricing situation in Peru

Medicines Transparency Alliance How has MeTA Peru undertaken this issue El Observatory of Prices is a component in the workplan of MeTA Peru. Production of a regulatory proposal with participation of associates to develop the Observatory. Deliverable of a regulatory proposal by MeTA Peru to the Ministry of Health for approval. Technological Support: Software and IT. Diffusion of the Observatory of Prices among the population. 02/02/20163

Medicines Transparency Alliance National Information System of Pharmaceutical Prices Objectives: To establish an information system that contribute to prevent monopolistic practices and segmentation of the market. To guarantee transparency of sales prices information that allows to adopt informed decisions in favour of users. Legal Framework: Ley Nº Law of Pharmaceutical Products, medical devices and sanitary products. RM Nº /MINSA ( ) RM Nº /MINSA, modification of Art. 4° de RM N° /MINSA ( )

Medicines Transparency Alliance REACH All pharmaceutical establishments, public and private (laboratories, drug stores, pharmacies and chemist’s shops) should be registered in the National System of Information of Prices of Pharmaceutical Products (SNIP-PF) by of the Regulating Authority of Medicines in charge - DIGEMID. Laboratories Drugstores Pharmacies Chemist’s Shops Public, Private, or Mixed Observatory of Prices of Pharmaceutical Products

Medicines Transparency Alliance TYPE OF INFORMACIÓN Laboratories Drugstores Pharmacies Chemist’s Shops Retail Prices (including discounts) Maximum Prices Minimum Prices Average Price Reporting frequency: At least once a month Observatory of Prices of Pharmaceutical Products

Medicines Transparency Alliance DATES R.M. Nº /MINSA Pharmaceutical Product Catalog FINAL Software Pharmaceutical Establishments report the prices July, 2010 May, 2010 August, 2010 Observatory of Prices of Pharmaceutical Products

Medicines Transparency Alliance Observatory of Prices of Pharmaceutical Products Version 2 (now) Price consultation process Factor: Substance, pharmaceutical form, geographical zone IMS SISMED Database Filter: Disponibility of Stock: 2 months Study: Estimation of the marketing margins

Medicines Transparency Alliance02/02/20169 Thank you Pedro Yarasca Telf.: